Share on StockTwits

Shares of DexCom (NASDAQ:DXCM) have earned an average rating of “Buy” from the twelve analysts that are currently covering the company, StockRatingsNetwork.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $37.90.

A number of research firms have recently commented on DXCM. Analysts at Sterne Agee upgraded shares of DexCom from a “neutral” rating to a “buy” rating in a research note on Thursday, April 10th. They now have a $50.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Thursday, March 27th. They now have a $44.00 price target on the stock.

In other DexCom news, SVP Andrew Balo sold 10,000 shares of DexCom stock on the open market in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $35.36, for a total transaction of $353,600.00. Following the transaction, the senior vice president now directly owns 159,099 shares of the company’s stock, valued at approximately $5,625,741. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of DexCom (NASDAQ:DXCM) traded up 2.25% during mid-day trading on Wednesday, hitting $34.93. The stock had a trading volume of 100,799 shares. DexCom has a 1-year low of $15.04 and a 1-year high of $49.83. The stock’s 50-day moving average is $42.77 and its 200-day moving average is $36.42. The company’s market cap is $2.543 billion.

DexCom (NASDAQ:DXCM) last released its earnings data on Thursday, February 20th. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.07) by $0.03. The company had revenue of $51.30 million for the quarter, compared to the consensus estimate of $48.53 million. Analysts expect that DexCom will post $-0.10 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.